MLYS
Mineralys Therapeutics, Inc.
$21.61
+0.69
(+3.30%)
Mkt Cap
1.85B
Volume
168,135
52W Range
20.12-47.65
Sector
Healthcare
Beta
0.69
EPS (TTM)
-4.24 USD
P/E Ratio
-15.85
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (154.65M) | (177.81M) | (71.90M) | (29.80M) | (19.41M) | (3.43M) |
| EPS | -2.29 | -3.66 | -1.99 | -5.77 | -3.89 | -0.74 |
| Free Cash Flow | (142.43M) | (166.41M) | (81.17M) | (29.22M) | (14.56M) | (2.46M) |
| FCF / Share | -2.11 | -3.43 | -2.24 | -5.66 | -2.92 | -0.53 |
| Operating CF | (142.42M) | (166.31M) | (81.17M) | (29.22M) | (14.56M) | (2.46M) |
| Total Assets | 661.81M | 205.90M | 251.64M | 114.44M | 11.12M | 1.49M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 4.50M |
| Cash & Equiv | 172.92M | 114.09M | 49.30M | 87.70M | 10.61M | 1.41M |
| Book Value | 646.69M | 191.26M | 241.15M | (52.27M) | (22.93M) | (3.60M) |
| Return on Equity | -0.24 | -0.93 | -0.30 | N/A | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (241.07M) | (39.34M) | (32.23M) | (36.93M) | (43.27M) | (42.21M) | (48.95M) | (56.34M) | (41.01M) | (31.51M) | (24.39M) | (22.76M) |
| EPS | -2.85 | -0.47 | -0.40 | -0.52 | -0.66 | -0.79 | -0.98 | -1.13 | -0.83 | -0.70 | -0.61 | -0.57 |
| Free Cash Flow | (32.56M) | (39.47M) | (37.90M) | (28.87M) | (30.17M) | (45.49M) | (66.84M) | (50.22M) | (30.15M) | (19.20M) | (28.98M) | (19.03M) |
| FCF / Share | -0.38 | -0.48 | -0.47 | -0.41 | -0.46 | -0.86 | -1.34 | -1.01 | -0.61 | -0.43 | -0.72 | -0.48 |
| Operating CF | (32.56M) | (39.47M) | (37.89M) | (28.87M) | (30.17M) | (45.49M) | (66.84M) | (50.19M) | (30.15M) | (19.14M) | (28.98M) | (19.03M) |
| Total Assets | 667.85M | 652.86M | 661.81M | 599.95M | 335.72M | 354.94M | 205.90M | 268.25M | 318.49M | 347.25M | 251.64M | 277.56M |
| Total Debt | 97.62M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 138.27M | 112.78M | 172.92M | 217.60M | 101.79M | 165.01M | 114.09M | 97.27M | 67.86M | 90.42M | 49.30M | 86.30M |
| Book Value | 550.92M | 638.14M | 646.69M | 576.43M | 313.55M | 341.56M | 191.26M | 236.93M | 290.10M | 328.05M | 241.15M | 264.01M |
| Return on Equity | -0.44 | -0.06 | -0.05 | -0.06 | -0.14 | -0.12 | -0.26 | -0.24 | -0.14 | -0.10 | -0.10 | -0.09 |
MLYS News
Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
Mineralys (NASDAQ: MLYS) CEO sells 75,000 shares under prearranged plan
Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026
Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics (NASDAQ:MLYS) Director Brian Taylor Slingsby Sells 104,320 Shares of Company Stock
Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
Mineralys Therapeutics' Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
Mineralys Therapeutics (NASDAQ:MLYS) Insider Eric Warren Sells 7,438 Shares